Biolidics
Biolidics (Embracing Future Holdings Limited, SGX: 8YY) is a Singapore-based medical device company that develops and commercializes the ClearCell FX1 System, an FDA-cleared IVD device using its patented CTChip FR1 microfluidic biochip to enrich circulating tumor cells from blood for pathology laboratories and oncology researchers.
- Company typePublic
- Founded2009
- HeadquartersSingapore, Singapore
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Biolidics does
Biolidics is the operating brand of Embracing Future Holdings Limited (EFH), a Singapore-incorporated, SGX-listed (ticker: 8YY) medical device company founded in 2009 that develops and commercializes the ClearCell FX1 System, a fully automated IVD medical device for label-free separation and enrichment of circulating tumor cells (CTCs) from blood. The system is built around the proprietary, patented CTChip FR1 microfluidic biochip, which isolates wholly intact and viable CTCs in liquid suspension that can be transferred to standard laboratory formats such as glass slides and microtiter plates for integration with routine pathology workflows. The company is headquartered at 122 Emerald Hill Road, Singapore, and serves pathology laboratories and oncology healthcare providers engaged in cancer diagnostics, liquid biopsy, and CTC research.
The company monetizes through hardware sales of the ClearCell FX1 System under a quote-based pricing model that is not publicly disclosed. Its go-to-market combines direct enterprise sales via a Request-for-Quotation channel on the corporate website with marketplace distribution through LabX, enabling access to both large laboratories and smaller research buyers. Beyond the oncology diagnostics franchise, EFH has publicly disclosed a strategic intent to diversify into technology-enabled lifestyle businesses, including Multi-Channel Networks, live streaming social e-commerce, and Esports-related operations. The company has raised approximately $11.7M in disclosed funding across a 2013 Series A led by Vertex Ventures and a 2018 round, and acquired Biomedical Laboratory in March 2020 for approximately $2.6M.
Biolidics firmographics
Firmographics- Name
- Biolidics
- Legal name
- Embracing Future Holdings Limited
- Website
- https://biolidics.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Biolidics (Embracing Future Holdings Limited, SGX: 8YY) is a Singapore-based medical device company that develops and commercializes the ClearCell FX1 System, an FDA-cleared IVD device using its patented CTChip FR1 microfluidic biochip to enrich circulating tumor cells from blood for pathology laboratories and oncology researchers.
- Ownership category
- akta.pro rank
Biolidics industry classification
Industry- Product category
- Cancer Diagnostics Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
- akta.pro secondary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Biolidics is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices1 record
Markets served
Biolidics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of the ClearCell FX1 System, a fully automated IVD medical device for CTC enrichment. Revenue generated through direct sales to laboratories and healthcare facilities, as well as through marketplace distribution.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for ClearCell FX1 System |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
Biolidics product offering
Product offeringCore offering
Biolidics develops and commercializes the ClearCell FX1 System, a fully automated in-vitro diagnostic (IVD) medical device that separates and enriches circulating tumor cells (CTCs) from blood samples using a patented microfluidic biochip (CTChip FR1). The system enables label-free, viable and intact CTC isolation that can be transferred to standard laboratory formats such as glass slides and microtiter plates for downstream pathology and oncology workflows.
Product overview
Biolidics offers a focused diagnostic product portfolio centered on the ClearCell® FX1 System, a fully automated IVD medical device for circulating tumor cell (CTC) enrichment. The system incorporates the proprietary CTChip® FR1 microfluidic biochip to achieve label-free separation of viable and intact cancer cells from blood samples. The isolated CTCs are collected in liquid suspension and can be transferred to standard laboratory formats such as glass slides and microtiter plates for integration with routine pathology workflows.
Differentiator
Problem solved
Functional benefit
Companies that use Biolidics
Customer profileSegments2 records
Ideal customer profiles2 records
Biolidics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Biolidics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- LabXminorLabX serves as a marketplace distribution channel for the ClearCell FX1 System, making the product available to a broader range of buyers including smaller research facilities and individual researchers through the LabX e-commerce platform.
Scale indicators1 record
Recent moves6 records
Expansion highlights4 records
Biolidics competitors and assessment
Company assessmentDirect peers
- Menarini Silicon Biosystems: Developer of CELLSEARCH, the first and only FDA-cleared CTC enumeration test. Direct competitor to Biolidics' ClearCell FX1 in circulating tumor cell enrichment from blood, targeting oncology research and clinical diagnostics laboratories.
- ANGLE plc: UK-listed developer of the Parsortix system, a label-free microfluidic CTC isolation platform. Direct technical competitor to Biolidics' ClearCell FX1, also addressing the liquid biopsy market with a size- and deformity-based CTC capture approach.
- RareCyte: US-based developer of the RareCyte platform for CTC identification and retrieval from blood. Comparable to Biolidics in offering instrumentation for intact CTC isolation for downstream oncology research and companion diagnostic applications.
- Epic Sciences: Developer of a CTC liquid biopsy platform for characterizing circulating tumor cells from blood. Comparable to Biolidics in serving oncology researchers and biopharma with CTC-based analysis tools.
- Biocept: US-based liquid biopsy company offering CTC and ctDNA-based oncology diagnostics. Smaller, single-platform peer comparable to Biolidics in targeting community oncology and pathology labs with blood-based cancer tests.
- ScreenCell: Developer of CTC isolation devices (ScreenCell products) for cancer research and liquid biopsy applications. Comparable niche player offering filtration-based CTC enrichment tools to research and clinical labs.
Broad incumbents
- Guardant Health: US-based leader in liquid biopsy, offering NGS-based ctDNA tests (Guardant360, Reveal) for oncology. While focused on ctDNA rather than CTCs, it is a broad incumbent defining the competitive landscape for blood-based cancer diagnostics that Biolidics operates in.
- Natera: Developer of cell-free DNA-based oncology tests (Signatera MRD) and reproductive health diagnostics. Larger commercial-stage incumbent in the liquid biopsy space where Biolidics competes for oncology lab budgets.
- Exact Sciences: US-based diagnostics company (Cologuard, Oncotype DX, OncoExTra) with a growing liquid biopsy franchise. Broad incumbent in oncology diagnostics whose expanding portfolio shapes demand for blood-based cancer tests.
Emerging players
- CytoLumina Technologies: Early-stage developer of microfluidic CTC isolation technologies spun out of academic research. Emerging player addressing overlapping niche applications in CTC enrichment for cancer diagnostics and research.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Biolidics social profiles
Digital presenceBiolidics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biolidics leadership team
Management profileNumber of profiles
Profiles3 records
Biolidics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biolidics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biolidics
What does Biolidics do?
Biolidics develops and commercializes the ClearCell FX1 System, a fully automated in-vitro diagnostic (IVD) medical device that separates and enriches circulating tumor cells (CTCs) from blood samples using a patented microfluidic biochip (CTChip FR1). The system enables label-free, viable and intact CTC isolation that can be transferred to standard laboratory formats such as glass slides and microtiter plates for downstream pathology and oncology workflows.
Is Biolidics a public or private company?
Biolidics is a public company. It is classified as public and is currently operating.
When was Biolidics founded?
Biolidics was founded in 2009. It employs 11 to 50 people.
Where is Biolidics based?
Biolidics is headquartered in Singapore, Singapore, in the Asia region.
How does Biolidics make money?
One revenue line is on record: medical Device Sales.
Who are Biolidics's main competitors?
Direct peers on record are Menarini Silicon Biosystems, ANGLE plc, RareCyte, Epic Sciences, Biocept and ScreenCell. Broad incumbents are Guardant Health, Natera and Exact Sciences. CytoLumina Technologies is listed as an emerging player.
Does Biolidics have an API?
No public API is recorded for Biolidics.
What industry is Biolidics in?
Biolidics's product category is Cancer Diagnostics Medical Devices. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays). Its NAICS code is 3391 and its SIC code is 3841.